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Abstract
Background: This study analyzes the clinicopathologic and radiologic characteristics of malignant serous cystic
neoplasm (SCN) of the pancreas through systematic review and an institutional case report.
Methods: A comprehensive literature search was performed in the MEDLINE database to identify studies on
malignant SCNs of the pancreas that had detailed clinicopathologic and radiologic information. A computerized
systematic search of our institutional database was also performed to identify cases of malignant SCN for addition
to the systematic review. Using the final included cases, we analyzed the clinicopathologic and radiologic features
of malignant SCNs of the pancreas.
Results: A review of 136 candidate articles identified 26 studies with 26 cases that had detailed clinical information.
Our institutional data search added one case. The systematic review of the 27 cases revealed that primary tumors
(mean diameter 10.2 ± 4.0 cm) mainly involved the body and tail of the pancreas (n = 16) and frequently invaded
adjacent organs (n = 19). Distant metastases occurred in 14 patients (synchronous, n = 5; metachronous, n = 8; both,
n = 1), most commonly in the liver (n = 13). Imaging features of malignant SCNs of the pancreas were identical to
the benign counterpart, except local invasion or distant metastases. The prognosis was excellent in that 17 were
alive at the time of writing with a median follow-up period of 2 years.
Conclusions: The malignant potential of SCNs of the pancreas should be considered in the diagnosis and
management of patients with pancreatic SCNs.
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resonance imaging
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Background
Serous cystic neoplasms (SCNs) of the pancreas are usu-
ally cystic epithelial neoplasms composed of cuboidal,
glycogen-rich, epithelial cells that produce serous fluid [1].
Pancreatic SCNs represent approximately 10–16 % of
all kinds of cystic pancreatic lesions [2–5]. Since
Compagno et al. classified cystic neoplasms of the pan-
creas into serous and mucinous types in 1978 [6], SCNs
were considered as a benign disease entity without risk
of malignant transformation. This concept changed after
George et al. reported the first case of a malignant SCN
of the pancreas in 1989 [7]. Thereafter, the number of
case reports or series of malignant SCNs of the pancreas
increased [4, 8–31]. Thus, SCNs of the pancreas are not
considered totally benign, but have an extremely low
malignant potential. Regarding the incidence of malig-
nant SCNs, the majority of literature reported less than
1 %, including the largest series which showed three ser-
ous cystadenocarcinomas from 2622 patients [32], even
though a few literature reported 1–5 % [5, 18, 33]. Due
to its very rare chance to be malignant, the vast majority
of SCNs are safely observed without resection [34].
As a result of their extreme rarity, the characteristics
of malignant SCNs of the pancreas were not well ex-
plored until the World Health Organization (WHO)
classification published in 2010 established the definition
of serous cystadenocarcinoma and described its charac-
teristics [1]. In the 2010 WHO classification, malignancy
is defined by the presence of distant metastases regard-
less of benign-looking histologic features. However, the
WHO classification is still under debate as many studies
have classified SCNs that invade surrounding organs as
malignant SCNs even though there is no distant metas-
tasis [4, 9, 12, 13, 16, 21, 22, 24, 25, 27, 29, 33]. There-
fore, in this article, we use the broad term ‘malignant
SCNs’ to include either SCNs with distant metastasis or
local invasion.
Despite the increasing number of cases of malignant
SCNs, there has been no systematic review to summarize
the variable presentations of malignant SCNs and to
provide a perspective of this rare disease entity.
Therefore, we performed a systematic review of the




A computerized search of the MEDLINE database was
conducted to find relevant studies published prior to
April 30, 2015. Studies were eligible for inclusion if they
described the clinicopathologic features, imaging find-
ings, treatment, and outcome of the cases with regard to
malignant SCNs of the pancreas. Any type of publication
including case reports or case series was eligible. The
following search terms were used: (pancreas OR pancre-
atic) AND (“serous cystadenocarcinoma” OR “serous
cystic neoplasm”). Our search did not set any restriction
or filter. To expand the search, the bibliographies of arti-
cles that remained after the selection process were
screened for other potentially suitable articles.
Institutional data search and case presentation
Our institutional review board approved the search of
electronic medical records for this study. We performed
a systematic computerized search of our institutional
database (ABLE, Asan Medical Center) from January
1996 to April 2015 using the diagnostic codes of ‘serous
cystic neoplasm of the pancreas’, ‘serous cystadenoma of
the pancreas’, and ‘serous cystadenocarcinoma of the
pancreas’. Using these search terms, we identified 447
patients initially diagnosed with SCN of the pancreas.
Among the 447 patients, only one case was confirmed as
serous cystadenocarcinoma of the pancreas. We ob-
tained an informed consent from the patient. We
present the clinical course, pathologic findings, and im-
aging features of this case. We also included this case in
the systematic review of malignant SCNs.
Analysis of clinicopathologic and radiologic features
For the malignant SCNs from the literature search and
our institution, we analyzed their clinicopathologic fea-
tures, patterns of metastasis and local invasion, treat-
ment, and outcome. When imaging features of the
primary tumors and/or metastatic tumors were available,
we also analyzed these imaging findings.
Results
Literature selection
Our study selection process is shown in Fig. 1. The lit-
erature search in the MEDLINE database generated 136
initial candidate articles. After reviewing the titles and
the abstracts and excluding 22 review articles, two con-
ference abstracts, and 80 articles that were not in the
field of interest for this study, 32 articles were initially
selected for eligibility. The full text of the 32 articles was
retrieved. The search of the bibliographies of these arti-
cles found four additional eligible studies. Among these
36 eligible studies with 42 cases, we further excluded
three articles that were not in the field of interest and
seven studies that did not have detailed information on
pancreatic serous cystadenocarcinomas, and selected 26
studies with 26 cases [4, 7–31]. We also included the
present case from our institution; thus finally 27 cases
were reviewed in this systematic review.
Presentation of our case
A 52-year-old woman presented to our institution with a
palpable abdominal mass. On physical examination, a
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large, soft mass was palpable in the epigastrium. Results
of laboratory examinations and tumor markers (carci-
noembryonic antigen and carbohydrate antigen 19–9)
were within the normal range. Serum chromogranin A
was 108 ng/mL, which was around the upper normal
limit (27–94 ng/mL). Contrast-enhanced computed tom-
ography (CT) scans showed a 9 × 8 cm solid and cystic
mass in the head of the pancreas (Fig. 2a). The per-
ipheral portion of the tumor was well enhanced, while
the central portion was not well enhanced. On 18F-
fludeoxyglucose (FDG) positron emission tomography
(PET)/CT scans, the tumor did not show any increased
uptake (Fig. 2b).
Pancreaticoduodenectomy was performed with a clin-
ical diagnosis of a solid pseudopapillary neoplasm or
pancreatic neuroendocrine tumor. On the gross speci-
men, a well-demarcated lobulated mass was observed in
the pancreas head. The cut surface showed a yellowish,
gray, firm tumor with multiple microcystic changes and
fibrous septa (Fig. 2c). Vascular and perivascular inva-
sions and nodal involvement were not observed. Micro-
scopic findings revealed multiple microcysts separated
by collagen fibers. The inner surface of the cysts was
lined by a single layer of cuboidal epithelium with a clear
cytoplasm (Fig. 2d). No mitoses or cellular atypia were
noted. Immunohistochemical staining was positive for
the cytokeratins, AE1 and AE3, and negative for CD56,
chromogranin A, synaptophysin, renal cell carcinoma
marker, and CD10. The epithelial cells of the tumor had
cytoplasmic periodic acid-Schiff (PAS)-positive granules.
The histopathological diagnosis was serous cystadenoma
of the pancreas.
Five years later, the patient presented with abdominal
discomfort. On contrast-enhanced CT, there were mul-
tiple liver masses/nodules that showed peripheral rim
enhancement (Fig. 2e). Under suspicion of liver metasta-
ses, FDG-PET scanning was performed, which revealed
no FDG avidity in any liver masses/nodules. There was
no evidence of local tumor recurrence or extrahepatic
metastasis on FDG-PET/CT scans and body CT. The
tumor showed very high signal intensity (SI) like cere-
brospinal fluid on T2-weighted magnetic resonance
(MR) image (Fig. 2f ) and low SI on T1-weighted image.
On diffusion-weighted images and apparent diffusion co-
efficient map, there was no diffusion restriction in the
tumor. On multiphasic contrast-enhanced T1-weighted
MR images, the tumor showed peripheral rim enhance-
ment in the arterial phase, portal-venous phase, and
delayed phase (Fig. 2g).
Ultrasound-guided biopsy was performed for the liver
masses. Pathologic results showed that the tumor speci-
men was composed of multiple microcysts separated by
collagen fibers (Fig. 2h). The microcysts were lined by a
single layer of cuboidal epithelium with a clear cyto-
plasm and bland-looking nuclei. These histopathologic
features were very similar to those of the previous
Fig. 1 Flow diagram for literature selection
Huh et al. BMC Gastroenterology  (2016) 16:97 Page 3 of 10
pancreaticoduodenectomy specimen. Finally, the histo-
logic diagnosis was confirmed as serous cystadenocarci-
noma with metachronous liver metastasis.
The patient has been observed without any treatment
for the liver metastases for 17 months after liver mass
biopsy. The liver metastases have minimally enlarged on
follow-up CT as the largest liver metastasis has increased
from 3.1 to 3.4 cm in the longest diameter over
17 months. However, the patient has been asymptomatic
and is still alive at the time of writing.
Fig. 2 A 52-year-old woman with malignant serous cystic neoplasm of the pancreas and metachronous hepatic metastasis. a Contrast-enhanced
CT scan demonstrates a 9 × 8 cm solid and cystic mass in the pancreatic head. b FDG-PET/CT scan demonstrates no increased uptake within the
tumor. c Photograph of the gross specimen shows a well-demarcated lobulated mass. The cut surface showed a yellowish, gray, firm tumor with
multiple microcystic changes and fibrous septa. d Photomicrograph shows multiple microcysts lined by a single layer of cuboidal epithelium with
a clear cytoplasm (H and E stain, ×200). e Contrast-enhanced CT scan shows a low-attenuating nodular lesion with peripheral rim enhancement
in liver segment VII. f On T2-weighted MR image, the liver tumor shows very bright signal intensity like cerebrospinal fluid. g On contrast-enhanced
T1-weighted MR image during the portal-venous phase, the tumor shows peripheral rim enhancement. h Photomicrograph shows that the tumor is
composed of multiple microcysts separated by collagen fibers, which are lined by a single layer of cuboidal epithelium with a clear cytoplasm and
bland-looking nuclei (H and E stain, ×200)
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Systematic review
The characteristics of the 27 included cases of malignant
SCNs are summarized in Table 1. The 27 cases were di-
agnosed as malignant SCNs of the pancreas because they
exhibited characteristics of malignancy including local
invasion and/or distant metastasis. According to the def-
inition of the 2010 WHO classification, which defines
pancreatic serous cystadenocarcinoma by the presence
of distant metastases, only 14 cases were pancreatic
serous cystadenocarcinoma. However, we also analyzed
the cases with local invasion.
Clinical features
The mean age of patients with malignant SCNs was 68.0
± 10.4 years with a range of 42–87 years. The female to
male ratio was 2.9 (20 females and seven males). Regard-
ing the presenting symptoms or signs, abdominal/flank
pain was the most commonly presented (n = 13; 48.1 %),
followed by a palpable mass (n = 6; 22.2 %), weight loss (n
= 5; 18.5 %), gastrointestinal bleeding (n = 3; 11.1 %), inci-
dental detection (n = 3; 11.1 %), and jaundice or abnormal
levels of serum liver enzymes (n = 3; 11.1 %).
Morphologic and radiologic features
On gross specimens, the most common pattern was the
microcystic type (n = 20), which is defined as multiple
cysts measuring <2 cm separated by thin fibrous septa.
The macrocystic type, which is composed of large cysts
≥2 cm, was observed in two cases. The mixed microcys-
tic and macrocystic type was found in two cases. There
was only one case with the solid type. In two articles,
there was no information on the gross morphological
type of SCN.
CT or MR imaging features were available in 20 cases,
in which the imaging features of the primary tumors
and/or metastatic lesions were qualitatively described. In
all cases, the imaging findings of the malignant SCNs of
the pancreas were basically identical to those of benign
serous cystadenoma, except for malignant behavior such
as local invasion or distant metastases. The radiologic
features of serous cystadenoma or cystadenocarcinoma
generally varied according to the gross morphologic
pattern. Tumors with the microcystic pattern were gen-
erally shown as well-circumscribed, multilocular masses,
with or without central stellate scars. The microcysts
were not clearly identified on CT, but were very hyperin-
tense on T2-weighted MR images. Tumors with the
macrocystic pattern were shown as well-circumscribed,
lobulated masses containing a few cysts. The SCNs with
a mixed microcystic and macrocystic type simultan-
eously showed findings of the micro- and macrocystic
types. The solid type of malignant SCN reported in one
case was shown as a solid enhancing mass that initially
mimicked a neuroendocrine tumor.
Regarding the malignant features, local invasion to
the adjacent vessels, spleen, liver, adrenal glands, stom-
ach, or colon could be detected on CT and/or MR
images. Among the 27 cases with malignant SCNs, 13
had hepatic metastasis. Seven of thirteen cases de-
scribed enhancement patterns and morphological char-
acteristics of the liver metastasis. Six synchronous or
metachronous metastases in the liver were cystic
masses with peripheral enhancement on contrast-
enhanced CT/MRI and showed very high SI on T2-
weighted images. Only one hepatic metastatic mass
showed heterogeneous wall enhancement; however, it
also demonstrated very high SI on T2-weighted images
like the other masses. Taking all into account, the liver
metastases, which are basically cystic masses, can be
characterized as exhibiting very high SI on T2-
weighted images, with an enhancing cyst wall and/or
fibrous septa.
Primary tumors and local invasion
The mean diameter of the primary pancreatic tumors
was 10.2 ± 4.0 cm (range, 2.5–19 cm). The locations of
the primary tumors were as follows: pancreatic head
(n = 7; 25.9 %), pancreatic body and tail (n = 9; 33.3 %),
pancreatic body (n = 5; 18.5 %), pancreatic tail (n = 2;
7.4 %), entire pancreas (n = 3; 11.1 %), or location un-
available (n = 1; 3.7 %).
Local invasion of the adjacent organs occurred in 19 pa-
tients (70.4 %) including six patients with invasion of mul-
tiple organs, as follows: adjacent vessels (n = 7; 25.9 %),
spleen (n = 5; 18.5 %), peripancreatic fat (n = 3; 11.1 %),
stomach (n = 3; 11.1 %), duodenum (n = 3; 11.1 %), colon
(n = 1; 3.7 %), liver (n = 1; 3.7 %), retroperitoneum (n = 1;
3.7 %), and perineural invasion (n = 1; 3.7 %).
Metastasis patterns
Among the 27 cases with malignant SCNs, 14 had a dis-
tant metastasis: synchronous metastases in five patients
(18.5 %), metachronous metastases in eight patients
(32 %), and both synchronous and metachronous metas-
tases in one patient (3.7 %). The time interval between
detection of pancreatic SCN and metachronous metasta-
ses was from 1 to 10 years (median, 3 years).
Among the 14 patients with distant metastases, includ-
ing two patients with metastasis in multiple organs, the
sites of distant metastases were as follows: liver (n = 13;
92.9 %), lung (n = 1; 7.1 %), bone (n = 1; 7.1 %), adrenal
glands (n = 1; 7.1 %), peritoneum (n = 1; 7.1 %), and
spleen (n = 1; 7.1 %). Notably, liver metastasis was found
in all patients with metachronous metastases. Among
the 27 patients, only four patients had lymph node me-
tastases; however, the exact site of lymph node metasta-
sis was unavailable.
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Table 1 Characteristics of included cases of malignant serous cystic neoplasms of the pancreas




























1990 74 F Right flank pain,
weight loss, palpable
mass




Synchronous None None Death due to
advanced neoplasm




10 Microcystic Neural invasion TP NA
Okada et al. 1991 63 F Abdominal pain body and
tail
12 Microcystic Liver Metachronous
(4 years)








12 Microcystic Liver Metachronous
(3 years)
None DP Alive 6 years after
initial operation
Ohta et al. 1993 64 M Unrelated incidental
detection of the tumor
on abdominal CT
body 2.5 Microcystic Perivascular and
vascular
invasion




1996 71 M Elevated liver function
tests
head 4 Mixed Peripancreatic
fat
PPPD Alive 1 year later
Ishikawa
et al.









16 Microcystic Liver Both (9 years) None DP, micorowave coagulo-
necrotic therapy
Alive 10 year after
initial operation





12 Microcystic Lymph node,
peripancreatic
fat
DP, splenectomy Alive 2 years later
Horvath
et al.
1999 81 F NA NA 6 NA Vessel DP NA
Wu et al. 1999 57 F Unrelated, incidental
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(3 years)































Table 1 Characteristics of included cases of malignant serous cystic neoplasms of the pancreas (Continued)




8 Microcystic Spleen DP, splenectomy Alive 1 year later








DP, splenectomy Alive 2 years later
Franko et al. 2008 68 F Flank pain, weight loss,
anemia, duodenal
bleeding





Inoperable Death due to
advanced neoplasm,
45 months later
King et al. 2009 70 M Abdominal pain,
hematemesis
head 9 Microcystic Duodenum PPPD Alive 7 years later
Vadala et al. 2010 74 M NA head NA NA Portal vein PD, portal vein
thrombectomy
NA
Bano et al. 2011 62 M Abdominal pain,
vomiting, weight loss,
jaundice
head 7 Microcystic Liver Metachronous
(1 year)
Duodenum PD, microwave coagulo-
necrotic therapy
Alive 1 year later
Cho et al. 2011 64 F Dizziness,
hematochezia
tail 12 Microcystic Colon, spleen
invasion
DP, segmental resection of
the colon, splenectomy
NA










Alive 1 year later
Rathore MU
et al.
2013 60 F Upper abdominal pain body 9 Microcystic Vessels Partial pancreatectomy and
splenectomy
Death 3rd post




2015 69 M Upper abdominal
discomfort




Alive 30 months later
Present
case
2015 52 F Palpable mass head 9 Microcystic Liver Metachronous
(5 years)
None PD Alive 6.5 years later
DP distal pancreatectomy, TP total pancreatectomy, PD pancreaticoduodenectomy, PPPD pylorus preserving pancreaticoduodenectomy














Regarding the treatment of primary tumors, surgical re-
section of the primary pancreatic SCN was performed in
23 patients (85.2 %). Three patients were inoperable due
to local invasion (n = 2) and synchronous metastases
(n = 1). In one case report focusing on histopathologic
features, the treatment was not stated [8].
Among the 27 cases, death was reported in five pa-
tients only, which was due to either an advanced pancre-
atic neoplasm (n = 2), perioperative mortality (n = 2), or
unrelated medical problem (n = 1). The two patients
who died from advanced tumors had metastasis in vari-
ous organs. Time to death ranged from 3 days to
45 months from the initial surgery or diagnosis. In 17
cases, patients were alive at the time of writing, with a
median follow-up period of 2 years (range, 9 months to
10 years from the initial surgery or diagnosis). Patient
outcomes were not reported for the other five patients.
Discussion
Our systematic review of malignant SCNs of the pan-
creas adds to growing evidence that SCNs of the pan-
creas have malignant potential. As a result of their
rarity, radiologists and clinicians generally consider
SCNs of the pancreas as benign. With the growing
number of malignant SCNs, we need to establish
diagnostic criteria for malignant SCNs of the pan-
creas. Regarding the primary tumors, malignant trans-
formation into cystadenocarcinoma is suggested by an
increase in size, heterogeneous morphological charac-
teristics, and poor distinction from the surrounding
pancreatic parenchyma [26]. Direct invasion of the
adjacent organs and the presence of distant metasta-
ses are hallmarks of malignant SCNs of the pancreas.
Although, the 2010 WHO classification defined malig-
nancy by the presence of distant metastases regardless
of benign-looking histologic features, the WHO classifica-
tion is still under debate as many studies have classified
SCNs that invade surrounding organs as malignant SCNs
[4, 9, 12, 13, 16, 21, 22, 24, 25, 27, 29, 33]. However, it is
difficult to differentiate local invasion from mass effect in
a large tumor, particularly on preoperative imaging stud-
ies. Particularly, it is more difficult to identify the presence
of local invasion in patients with SCNs as SCN is a cystic
tumor. Therefore, the definition of local invasion in SCNs
on imaging studies should be more clearly established like
that of vascular invasion in solid tumors. The vascular in-
vasion in solid tumors is usually defined as an encasement
of the vessel (greater than 180° vascular circumferential
involvement) or irregular narrowing of the vessel with
involvement of vessel wall by the tumor [35].
Interestingly, in nine cases with metachronous distant
metastasis, liver metastases occurred after complete re-
section of the primary tumor with the time interval
ranging from 1 to 10 years. Therefore, follow-up imaging
exams should include the liver. The liver metastases
from serous cystadenocarcinoma are frequently cystic in
nature with a similar histology to that of the primary
pancreatic tumor. T2-weighted images might be the
most important sequence for characterizing liver metas-
tases. When new multiseptated cystic lesions are de-
tected in the liver after resection of SCNs of the
pancreas, the possibility of metachronous liver metasta-
ses should be considered.
Synchronous liver metastases occurred in five cases
when the primary pancreatic SCNs were diagnosed. The
imaging features of liver metastases were similar to those
of primary pancreatic SCNs. Therefore, when multisep-
tated cystic lesions compatible with SCNs are found in
the liver and pancreas, we should consider the possibility
of pancreatic SCNs with synchronous liver metastases
from the initial diagnostic step, despite its rarity. In these
cases, a more vigorous diagnostic work-up is needed.
Regarding the outcome of those included studies, two
died from perioperative mortality, one died from unre-
lated medical problem, and two died from advanced tu-
mors. The other 17 patients were alive at the time of
writing. These findings indicate that surgical resection
should be decided very carefully due to high periopera-
tive mortality and relatively indolent course of malignant
SCNs. In current status, it is difficult to find predictive
factors for death due to small number of death cases,
warranting further evidence.
Nowadays, clinicians have a dilemma in the manage-
ment of SCN of the pancreas [35]. In general, the
current management of serous cystadenomas of the
pancreas is essentially conservative. Indeed, the vast ma-
jority of cases do not need surveillance after initial diag-
nosis. Surgery is indicated in cases with new symptoms
or complications such as abdominal pain, pancreatitis,
and biliary obstruction [28]. Since the malignant poten-
tial in the pancreatic SCNs is very low, pancreatic SCNs
can be safely observed without surgical resection in the
vast majority of cases. However, due to its malignant
potential, we need to establish certain criteria for the
surveillance of SCN of the pancreas. A comprehensive
panel of patient’s symptoms/signs, imaging, cytopathol-
ogy, tumor growth rate, and biological activity is essen-
tial for decision making. Thus, regular physical exam,
serum tumor markers, imaging studies including CT or
MRI, endoscopic ultrasonography, and cyst fluid analysis
should be performed appropriately.
Our study has limitations. First, it is a systematic lit-
erature review, hence the data such as malignant im-
aging features or local invasion were extracted from
individual studies. The presence of malignant imaging
features or local invasion were determined based on the
imaging description in individual studies. Second, all
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cases were gathered from different institutions where
the clinical practice might vary, which may raise issue of
heterogeneity of included cases. However, this is also an
inevitable limitation of a systematic literature review.
Conclusions
In conclusion, the number of reported cases of malig-
nant SCNs of the pancreas is growing, prompting radiol-
ogists and clinicians to redefine this disease entity and
establish guidelines for diagnosis and management of
malignant SCNs of the pancreas. A comprehensive panel
of patient’s symptoms/signs, imaging, cytopathology,
tumor growth rate, and biological activity is essential to
diagnose and manage malignant SCNs of the pancreas.
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